Pravastatin Reduces Liver Cancer in Rats
Author Information
Author(s): M Tatsuta, H Iishi, M Babal, K Iseki, H Yanol, H Uehara, R Yamamoto, A Nakaizumi
Primary Institution: Osaka Medical Center for Cancer and Cardiovascular Diseases
Hypothesis
Does pravastatin inhibit hepatocarcinogenesis induced by N-nitrosomorpholine in rats?
Conclusion
Pravastatin significantly suppresses the development of liver cancer in rats exposed to a carcinogen.
Supporting Evidence
- Pravastatin reduced the incidence, number, and volume of visible white nodules in treated rats.
- Histological analysis showed significant reductions in hepatic lesions in pravastatin-treated groups.
- Pravastatin increased apoptotic indices in neoplastic nodules.
Takeaway
Pravastatin helps prevent liver cancer in rats by stopping cancer cells from growing.
Methodology
Sixty male Sprague-Dawley rats were divided into three groups, with two groups receiving pravastatin and one group as a control, and were monitored for liver lesions after exposure to a carcinogen.
Limitations
The study was conducted on rats, and results may not directly translate to humans.
Participant Demographics
Young male Sprague-Dawley rats, 6 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website